Gilmore O'Neill, Chief Executive Officer of Editas Medicine, Inc. (NASDAQ: EDIT), sold 15,380 shares of common stock totaling $41,542 on June 3, 2026, according to a recent Form 4 filing with the Securities and Exchange Commission. The sale was executed at a weighted average price of $2.7011 per share, with individual trades occurring within a price range of $2.7010 to $2.7250. This transaction was not a discretionary trade by Mr. O'Neill. Instead, it was conducted under a durable automatic sales instruction plan adopted on April 13, 2022, and represents shares sold by the company to meet tax withholding obligations stemming from the vesting of restricted stock units on June 2, 2026. Following this transaction, Mr. O'Neill directly holds 248,313 shares of Editas Medicine common stock. In other recent news, Editas Medicine Inc. announced the pricing of an underwritten public offering, which includes 55,555,556 shares of common stock and warrants to purchase an equal number of shares. The combined price for each share and warrant is set at $2.25, with the offering expected to generate approximately $125 million in gross proceeds, before underwriting discounts and commissions. Cantor and Wells Fargo Securities are serving as joint book-running managers for this offering. The announcement of this stock offering led to a 14.1% drop in Editas Medicine's shares during premarket trading. Editas Medicine presented preclinical data for its gene editing treatment candidate, EDIT-401, at the European Atherosclerosis Society Congress and the American Society of Gene and Cell Therapy annual meeting. The data demonstrated that a single dose of EDIT-401 achieved a mean reduction of 90% or greater in LDL cholesterol, lipoprotein(a), and apolipoprotein B in non-human primates. These reductions were found to be rapid and dose-dependent, with a significant increase in hepatic LDLR protein levels. These developments reflect the company's ongoing efforts to advance its gene editing therapies. The sale comes as the stock has declined roughly 14% over the past week, though shares remain up 66% over the last year. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform offering detailed Fair Value estimates and 12 additional ProTips for investors. Editas Medicine's stock price was $2.71 at market close, down $0.28 or 9.36%. After hours trading saw the stock at $2.65, down $0.06 or 2.21%.
Gilmore O'Neill, Chief Executive Officer of Editas Medicine, Inc. (NASDAQ: EDIT), sold 15,380 shares of common stock totaling $41,542 on June 3, 2026, according to a recent Form 4 filing with the Securities and Exchange Commission. The sale was executed at a weighted average price of $2.7011 per share, with individual trades occurring within a price range of $2.7010 to $2.7250. This transaction was not a discretionary trade by Mr. O'Neill. Instead, it was conducted under a durable automatic sales instruction plan adopted on April 13, 2022, and represents shares sold by the company to meet tax withholding obligations stemming from the vesting of restricted stock units on June 2, 2026. Following this transaction, Mr. O'Neill directly holds 248,313 shares of Editas Medicine common stock. In other recent news, Editas Medicine Inc. announced the pricing of an underwritten public offering, which includes 55,555,556 shares of common stock and warrants to purchase an equal number of shares. The combined price for each share and warrant is set at $2.25, with the offering expected to generate approximately $125 million in gross proceeds, before underwriting discounts and commissions. Cantor and Wells Fargo Securities are serving as joint book-running managers for this offering. The announcement of this stock offering led to a 14.1% drop in Editas Medicine's shares during premarket trading. Editas Medicine presented preclinical data for its gene editing treatment candidate, EDIT-401, at the European Atherosclerosis Society Congress and the American Society of Gene and Cell Therapy annual meeting. The data demonstrated that a single dose of EDIT-401 achieved a mean reduction of 90% or greater in LDL cholesterol, lipoprotein(a), and apolipoprotein B in non-human primates. These reductions were found to be rapid and dose-dependent, with a significant increase in hepatic LDLR protein levels. These developments reflect the company's ongoing efforts to advance its gene editing therapies. The sale comes as the stock has declined roughly 14% over the past week, though shares remain up 66% over the last year. According to InvestingPro analysis, the stock appears undervalued at current levels, with the platform offering detailed Fair Value estimates and 12 additional ProTips for investors. Editas Medicine's stock price was $2.71 at market close, down $0.28 or 9.36%. After hours trading saw the stock at $2.65, down $0.06 or 2.21%.
Key Points
- CEO Gilmore O'Neill sold 15,380 shares for $41,542 on June 3, 2026, under an automatic sales instruction plan to cover tax withholding from vested restricted stock units.
- Editas Medicine priced an underwritten public offering of 55,555,556 shares and warrants at $2.25 per unit, expected to raise ~$125 million gross, with Cantor and Wells Fargo as joint book-running managers.
- The company presented preclinical data for EDIT-401 at the European Atherosclerosis Society Congress and the American Society of Gene and Cell Therapy annual meeting, showing a mean reduction of 90% or greater in LDL cholesterol, lipoprotein(a), and apolipoprotein B in non-human primates.
Risks
- The announcement of the stock offering led to a 14.1% drop in Editas Medicine's shares during premarket trading, indicating potential market sensitivity to dilution.
- The stock has declined roughly 14% over the past week, though shares remain up 66% over the last year, reflecting recent volatility.
- The preclinical data for EDIT-401 was presented in non-human primates, and the article does not provide information on human clinical trial timelines or outcomes.